TG Therapeutics Reports $616M Revenue for 2025, Targets Up to $900M in 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Source: Benzinga
- 2025 Revenue Expectations: TG Therapeutics reported a preliminary global revenue of approximately $616 million for fiscal year 2025, with Q4 U.S. net product revenue for BRIUMVI at around $182 million, indicating solid market performance despite the unaudited status of the financial figures.
- 2026 Revenue Outlook: The company targets total global revenue of $875 million to $900 million for 2026, with expected U.S. net product revenue for BRIUMVI between $825 million and $850 million, reflecting confidence in future growth driven by new product launches and market expansion.
- Operating Expense Forecast: TG Therapeutics anticipates operating expenses of approximately $350 million for 2026, plus $100 million for BRIUMVI inventory build and secondary manufacturer start-up costs, which will impact profitability and cash flow management.
- Technical Signal Analysis: Despite a 11.23% increase in stock price to $31.00, technical indicators suggest an overall bearish trend, with the 50-day moving average crossing below the 200-day moving average, indicating cautious market sentiment and the need for investors to monitor the key support level at $30.00.
Analyst Views on TGTX
Wall Street analysts forecast TGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TGTX is 43.50 USD with a low forecast of 15.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 30.680
Low
15.00
Averages
43.50
High
60.00
Current: 30.680
Low
15.00
Averages
43.50
High
60.00
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
